|

FC084CSA+Tislelizumab combination (dose escalation) Clinical Trials

1 actively recruiting trial

Also known as: FC084CSA+BGB-A317 combination (dose escalation)

Pipeline

Phase 1/2: 1

Top Sponsors

  • FindCure Biosciences (ZhongShan) Co., Ltd.1

Indications

  • Advanced Malignant Solid Tumors1
  • Cancer1

Other1 trial

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.